BC3 Technologies is a medical device company focused on transforming how bleeding emergencies are managed outside of hospitals. The company develops and commercializes advanced hemostatic technologies designed to stop severe bleeding quickly and simply. Their flagship product, SEAL Hemostatic Wound Spray, delivers professional-grade bleeding control in a format that can be used by anyone, anywhere. BC3’s mission is to put lifesaving trauma care directly into the hands of everyday people.
What are the main areas of activity of the company?
Our core activities are medical device innovation, commercialization of bleeding control products, and expansion of trauma preparedness solutions. We design next-generation hemostatic technologies, manufacture scalable medical products, and distribute them across consumer, professional, and institutional markets. The goal is to build a global platform for modern bleeding control that serves both everyday users and trained responders.
What’s the news about new products/services?
We are actively expanding the SEAL platform. In addition to our OTC and PRO aerosolized hemostatic spray, we are developing additional product formats and new kit configurations designed for home safety, travel, and workplace preparedness. We are also working on a non-aerosolized version of the technology to expand the range of use cases. These innovations will allow us to build a broader ecosystem of bleeding control tools.
What are the ranges of products/services?
Our current product line includes SEAL Hemostatic Wound Spray and a growing portfolio of bleeding control kits designed for different environments. These include everyday carry kits, home safety kits, workplace preparedness kits, and products designed for outdoor recreation and travel. As we continue to expand, our portfolio will include additional hemostatic delivery systems and complementary trauma care products.
What is the state of the market where you are currently active?
The bleeding control market is experiencing significant growth. Public awareness around emergency preparedness is rising, and programs such as Stop the Bleed have helped drive demand for bleeding control solutions outside traditional medical settings. Governments, organizations, and consumers increasingly recognize that the first person on scene during an emergency is often a bystander. That reality is creating strong demand for simple and effective bleeding control technologies.
What can you tell us about market trends?
One of the most important trends is the shift toward empowering individuals to act before professional help arrives. People want tools that are intuitive, portable, and effective under pressure. At the same time, institutions are prioritizing preparedness and resilience. This is pushing innovation toward simplified delivery systems, compact trauma kits, and technologies that reduce the training barrier required to save a life.
What are the most innovative products/services marketed?
SEAL Hemostatic Wound Spray represents a new approach to bleeding control. Traditional hemostatic products rely on powders or gauze that require a level of training and dexterity to apply effectively. SEAL uses an aerosol delivery system that allows rapid and even application directly to the wound surface. This simplifies bleeding control dramatically and makes advanced trauma care accessible to people without medical training.
What estimations do you have for the beginning of 2026?
As we move into 2026, we expect continued acceleration in both market adoption and product expansion. Our focus is scaling production, expanding into new markets, and continuing to innovate within the bleeding control category. We believe the next generation of trauma care will prioritize simplicity, accessibility, and speed, and BC3 Technologies is positioned to lead that shift.
